Speciality Medicines Limited has closed the trading window for insiders effective October 1, 2026. The restriction remains in force until 48 hours after the declaration of unaudited standalone financial results for the half year ended September 30, 2026.

Regulatory compliance and timeline

The closure is implemented pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended, and the company's Code of Internal Procedures and Conduct for Prevention of Insider Trading in Securities. This measure ensures that designated persons do not trade in equity shares while possessing unpublished price-sensitive information regarding the upcoming quarterly results.

The restriction period aligns with BSE Circular no. LIST/COMP/01/2019-20 dated April 2, 2019, which clarifies trading restriction periods. It also adheres to the Securities and Exchange Board of India (Prohibition of Insider Trading) (Second Amendment) Regulations, 2019.

Key dates for insiders

The company, formerly known as Speciality Medicines Private Limited, notified BSE Limited of this development on September 28, 2026. The notice was signed by Sumit Goyani, Whole Time Director, confirming that the trading window for dealing in equity shares is closed for all insiders covered under the company's code.

Speciality Medicines Limited concluded its 5th Annual General Meeting (AGM) on September 28, 2026, with shareholders unanimously approving all proposed resolutions. The meeting, conducted via video conferencing, saw a total of 5,534,760 votes polled in favor of both agenda items, with zero votes cast against.

The primary resolutions involved the adoption of audited financial statements for the fiscal year ended March 31, 2026, and the re-appointment of Sumit Goyani as Whole-Time Director. The company reported that no invalid votes were recorded during the remote e-voting process managed by National Securities Depository Limited (NSDL).

Voting participation and turnout

The AGM was held virtually via the ZOOM platform, with the registered office serving as the deemed venue. Out of 410 shareholders on the record date of September 21, 2026, 13 participants attended the meeting through video conferencing. This included five from the promoter group and eight from the public category. No physical attendance was recorded as per MCA circulars permitting virtual meetings.

Remote e-voting commenced on September 25, 2026, and closed on September 27, 2026. During the meeting itself, an additional facility for remote electronic voting was available for attendees who had not previously voted.

Resolution outcomes

Both ordinary resolutions were passed with 100% support from the votes polled. The detailed breakdown of voting results is presented below:

The scrutinizer’s report confirmed that the promoter group held 3,815,500 shares, while public non-institutional shareholders held 4,970,296 shares. Public institutional shareholders held no shares eligible for voting in this instance.

What the numbers show

A significant concentration of voting power was evident in the promoter group, which held approximately 43.4% of the total shares held by voting categories (3,815,500 out of 8,785,796 total shares considered). However, the actual turnout among public non-institutional shareholders was notably lower compared to the promoters. While promoters voted 99.08% of their held shares, public non-institutional shareholders voted only 35.29% of their holdings. This disparity highlights a strong alignment within the promoter group but relatively passive engagement from the broader retail shareholder base regarding routine governance matters like financial statement adoption.